Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0825 • ACR Convergence 2025
Rheum2Learn: A Randomized Trial of Virtual vs Text-Based Rheumatology Modules
Sonam Kiwalkar¹, Julianna Desmarais², Ellen Snyder³, Lisa Schroeder⁴, Marissa Meissner⁵, Noelle A. Rolle⁶, Sarah Donohue⁷, Brittany Bettendorf⁸, Ira Khanna⁹, Karen Kruzer¹⁰, Nkechi Emejuaiwe¹¹, Ibtissam Gad¹², David Leverenz¹³, Michael George¹⁴, Ashima Makol¹⁵, Floranne Ernste¹⁵ and Jilie Blaszczak¹⁶, ¹The Vancouver Clinic, Portland, OR, ²Oregon Health and Sciences University, Portland, OR, ³UNC Rheumatology, Chapel Hill, NC, ⁴Geisinger, Danville, PA, ⁵Geisinger Medical Center, Danville, PA, ⁶Medical College of Georgia at Augusta University, Evans, GA, ⁷University of Wisconsin, Madison, WI, ⁸University of Iowa, Iowa City, IA, ⁹Mount Sinai Hospital, New York, NY, ¹⁰Assistant Professor- University of Rochester, Victor, NY, ¹¹Cincinnati VA Medical Center, Cincinnati, OH, ¹²University of Michigan, Plymouth, MI, ¹³Duke University, Durham, NC, ¹⁴University of Pennsylvania, Philadelphia, PA, ¹⁵Mayo Clinic, Rochester, MN, ¹⁶University of Michigan, Ann Arbor, MI
Background/Purpose: Internal medicine (IM) residents often receive limited rheumatology training, contributing to low confidence in managing rheumatologic conditions and suboptimal performance on standardized examinations. Virtual…
Abstract Number: 0373 • ACR Convergence 2025
Implementation of a Lupus Self-Management mHealth App: Using Incentives to Drive Engagement
Melissa French¹, Katherine Carpenter², Eric Johnson², Melicent Miller² and Mary Crimmings², ¹Lupus Foundation of America, Alexandria, VA, ²Lupus Foundation of America, Washington, DC
Background/Purpose: As part of a five-year cooperative agreement with the Centers for Disease Control and Prevention, the Lupus Foundation of America (LFA) has implemented the…
Abstract Number: 0126 • ACR Convergence 2025
Performance of the 2023 and 2006 APS Classification Criteria in Pediatric Patients Diagnosed with APS: A Multisite Cohort Study
Jacqueline Madison¹, Elizabeth Sloan², Cristina Saez³, Olivia Kwan⁴, Kevin Lewis¹, Jonathan Marilao⁵, Blake Baay⁶, Rasha Elrefai⁴, Marissa Dale⁷, Deborah McCurdy⁸, Jheel Bhatt⁹, Sasidhar Goteti¹⁰, Ekemini Ogbu¹¹, Jason S. Knight¹ and Yu (Ray) Zuo¹, ¹University of Michigan, Ann Arbor, MI, ²UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ³Children's Hospital Colorado, Glendale, CO, ⁴Baylor College of Medicine, Houston, TX, ⁵University of Texas Southwestern, Dallas, TX, ⁶Scottish Rite for Children, Dallas, TX, ⁷Hospital for Special Surgery/NYP Cornell, New York, NY, ⁸UCLA Medical Center, Los Angeles, CA, ⁹Advent Health Orlando, Orlando, FL, ¹⁰University of Utah, Salt Lake City, UT, ¹¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Antiphospholipid syndrome (APS) is a thrombo-inflammatory disorder that causes significant morbidity and mortality, even in children. The 2023 ACR/EULAR classification criteria, which use weighted…
Abstract Number: 2647 • ACR Convergence 2025
Unlinked Paths to SLE: Divergent Associations of DNA Methylation and Polygenic Risk Scores with SLE Features
Holme Vestin¹, Nina Oparina¹, Elisabeth Skoglund¹, Maija-Leena Eloranta¹, Martina Frodlund², Iva Gunnarsson³, Chrisopher Sjöwall², Elisabet Svenungsson⁴, Lars Rönnblom¹, Juliana Imgenberg-Kreuz¹ and Dag Leonard¹, ¹Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: The aetiopathogenesis of SLE encompasses genetic and epigenetic factors, including hypomethylation of type I interferon (IFN) regulated genes (1) and the HLA-DRB1*03:01 haplotype, linked…
Abstract Number: 2565 • ACR Convergence 2025
Assessing Participation in the Lupus Sister Circle Support Group
Khadija Dantata, Wendy Rodgers and Lety Ocana, The Lupus Foundation of America, Washington, DC
Background/Purpose: Relative to White people with lupus (PWL), Black/African American (B/AA) PWL are three times as likely to develop lupus and suffer a severe form…
Abstract Number: 2456 • ACR Convergence 2025
Predictors of Real-World Remission in Patients with SLE Initiating Belimumab in the USA
Aarat M Patel¹, Renee L. Gennarelli², Temitope Bello², Ali Bonakdar² and Karen Worley³, ¹GSK, US Medical Affairs, Durham, NC, ²Cencora, Real-World Evidence, Conshohocken, PA, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA
Background/Purpose: The Definition Of Remission in SLE (DORIS) criteria were developed to align SLE remission definitions.1,2 Post hoc analyses of clinical trial data demonstrated that…
Abstract Number: 2440 • ACR Convergence 2025
Effect of Cenerimod on Four Main Clinical Items of SLEDAI-2K Score in SLE Patients in a Phase 2b Study
Anca Askanase¹, Bruno Flamion², Ouali Berkani² and Cecile Dubois², ¹Columbia University Medical Center, New York, NY, ²Viatris Innovation, Allschwil, Switzerland
Background/Purpose: Cenerimod is a selective S1P1 receptor modulator that has the potential to reduce the abnormal immune response seen in Systemic lupus erythematosus (SLE) thereby…
Abstract Number: 2421 • ACR Convergence 2025
Whole Blood Immune Phenotyping Reveals Cytometric Differences in B Cell Clusters Between Lupus Nephritis and Non-Lupus Nephritis SLE Patients with Minimal Proteinuria
Nicholas Bauer¹, Philip Carlucci², Rufei Lu¹, Carla Guthridge¹, Tayte Stephens³, Benjamin Jones⁴, Wade DeJager⁵, Susan Macwana¹, Andrea Fava⁶, Sanchit Sanyal⁷, Erin Carter⁸, Mala Masson⁹, Jennifer Anolik¹⁰, Jennifer Barnas¹¹, Peter Izmirly¹², H Michael Belmont¹³, Kelly Ruggles¹⁴, Study Team ALE⁰⁶ Clinical¹, Brad Rovin¹⁵, Jill Buyon¹⁶, Michelle Petri¹⁷, Judith James¹ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²New York University School of Medicine, New York, NY, ³University of Oklahoma Health Science Center, Oklahoma City, OK, ⁴Oklahoma State University, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶Johns Hopkins University, Baltimore, MD, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸New York University Grossman School of Medicine, New York, NY, ⁹NYU Langone Medical Center- Division of Rheumatology, New York, NY, ¹⁰University of Rochester Medical Center, Rochester, NY, ¹¹University of Rochester, Rochester, NY, ¹²New York University Grossman School of Medicine, New York, NY, ¹³NYU School of Medicine, New York, NY, ¹⁴NYU Grossman School of Medicine, Brooklyn, NY, ¹⁵The Ohio State University, Columbus, OH, ¹⁶NYU Grossman School of Medicine, New York, NY, ¹⁷Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Autoreactive B cell populations play a key role in the pathogenesis of lupus nephritis (LN). Therefore, it is hypothesized that dysregulation in the B…
Abstract Number: 2404 • ACR Convergence 2025
Clinical features of Elderly-onset Systemic Lupus Erythematosus
Jessica Dai¹, Erin Carter², Mala Masson³, Amit Saxena⁴, H Michael Belmont⁵, Peter Izmirly⁶ and Jill Buyon⁴, ¹New York University Grossman School of Medicine, Tenafly, NJ, ²New York University Grossman School of Medicine, New York, NY, ³NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁴NYU Grossman School of Medicine, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶New York University Grossman School of Medicine, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystemic chronic disease characterized by a wide range of clinical and serological manifestations. It most commonly affects young…
Abstract Number: 2387 • ACR Convergence 2025
Lupus Damage Index Revision – Item Generation and Reduction Phases
Burak Kundakci¹, Megan Barber², Ann Clarke², Sindhu Johnson³ and Ian Bruce⁴, ¹Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ²Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, United Kingdom
Background/Purpose: The current Systemic Lupus Erythematosus Damage Index (SDI) is a robust instrument, but is limited by missing items, restricted applicability in pediatric patients, and…
Abstract Number: 2221 • ACR Convergence 2025
Racial Differences in Cardiovascular Events and Adverse Pregnancy Outcomes Among Pregnant Individuals With Systemic Lupus Erythematosus
Rashmi Dhital¹, Rebecca Baer² and Christina Chambers³, ¹Vanderbilt University Medical Center, Brentwood, TN, ²University of California San Diego, San Diego, CA, ³University of California, San Diego, La Jolla, CA
Background/Purpose: Pregnant individuals with systemic lupus erythematosus (SLE) face an increased risk of cardiovascular events (CVEs) as well as adverse pregnancy outcomes (APOs). While racial…
Abstract Number: 2025 • ACR Convergence 2025
Spectrum of Autoantibodies in CNS Demyelinating Diseases: Clinical, Laboratory and Imaging Associations
Anna Rapti¹, Dimitris Karathanasis², Sylvia Raftopoulou¹, Charalampos Skarlis¹, Clio Mavragani¹ and Maria Eleftheria Evangelopoulos², ¹Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ²First Department of Neurology, School of Medicine, Eginition Hospital, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece
Background/Purpose: Systemic autoimmune diseases (SADs) may present with CNS demyelination, mimicking multiple sclerosis (MS), though driven by distinct immunopathogenic mechanisms. While ANA and aPL are…
Abstract Number: 1887 • ACR Convergence 2025
Incidence, Prevalence and Mortality of Systemic Lupus Erythematosus – A 20-year territory-wide analysis of electronic health records in Hong Kong
Danting zhang¹, jiaxin S. Wu¹ and Desmond Yat-Hin Yap², ¹The University of Hong Kong, Hong Kong, Hong Kong, ²Department of Medicine, The University of Hong Kong, Hong Kong SAR, Hong Kong
Background/Purpose: Advancements in immunosuppressive treatments and general medical care in the past two decades have influenced the disease burden and outcomes of patients with systemic…
Abstract Number: 1838 • ACR Convergence 2025
Differential Expression Of Activation Markers On dsDNA-reactive B-cells Between Healthy Subjects And SLE Patients Reveals Unconventional Extrafollicular Activation In SLE
Lars Van Vliet, Annemarie Dorjée, René Toes and Jolien Suurmond, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-dsDNA IgG antibodies are a hallmark of systemic lupus erythematosus (SLE), an autoimmune disease characterized by chronic inflammation and multi-organ damage. Evidence suggests that…
Abstract Number: 1745 • ACR Convergence 2025
High Emotional Distress Predicts Suboptimal Cardiovascular Health Among Patients with Juvenile-Onset Lupus and Dermatomyositis: Longitudinal Analysis of the Lupus Erythematosus and Dermatomyositis Stress and Cardiovascular Health Cohort Study
Kaveh Ardalan¹, Angel Davalos¹, Hwanhee Hong¹, Bryce Reeve¹, Christoph Hornik¹, M. Anthony Moody¹, Donald Lloyd-Jones², Eveline Wu³, Audrey Ward⁴, Simisola Gbadegesin⁵, Rebecca Sadun⁶, Jeffrey Dvergsten⁷, Lauren Covert¹, Ann Reed¹, Mark Connelly⁸ and Laura Schanberg⁹, ¹Duke University School of Medicine, Durham, NC, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³UNC Chapel Hill, Chapel Hill, NC, ⁴Children's National Hospital, Washington, DC, ⁵Wake Forest University School of Medicine, Winston-Salem, NC, ⁶Duke University, Durham, NC, ⁷Duke University Hospital, Hillsborough, NC, ⁸Children’s Mercy Kansas City/University of Missouri-Kansas City School of Medicine, Kansas City, MO, ⁹Duke University Medical Center, DURHAM, NC
Background/Purpose: Juvenile lupus & dermatomyositis (JSLE/JDM) patients experience high emotional distress and premature loss of cardiovascular health (CVH), defined as protective factors against cardiovascular disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].